Bristol’s Plavix woes continue
Executive Summary
Bristol-Myers Squibb has received a subpoena from the New York Attorney General's office for documents relating to its settlement with Apotex over Plavix (clopidogrel), the company announces April 26. The proposed deal, which was denied antitrust clearance by the Federal Trade Commission, is also being investigated by the Department of Justice (1"The Pink Sheet" Aug. 7, 2006, p. 9). In addition, the company announces April 26 that it has received a Civil Investigative Demand by the FTC requesting documents related to the proposed settlement. Bristol maintains that it is impossible at this time to assess the impact of the investigations, if any, on the company's compliance with the Deferred Prosecution Agreement with the United States Attorney's Office for the District of New Jersey. The deferred prosecution agreement is part of a 2004 settlement Bristol entered into with the SEC and DOJ over allegations of "channel stuffing," under which the company has two years to comply with all terms of the settlement or face prosecution (2"The Pink Sheet" June 20, 2005, p. 17)...
You may also be interested in...
Bristol $300 Mil. DoJ Settlement Includes Separation OF CEO/Chairman Roles
Bristol-Myers Squibb board member James Robinson will take on additional corporate governance oversight responsibilities, including meeting with execs prior to analyst calls, as the newly-appointed chairman
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.